New drug combo trial offers hope for aggressive blood cancer

This study is testing whether adding the immunotherapy drug Sintilimab to a standard chemotherapy regimen is safe and effective for people newly diagnosed with an advanced form of a rare and aggressive blood cancer called NK/T-cell lymphoma. The trial will enroll 34 adults to see if the combination leads to complete remission and improves survival. Researchers will also check if a specific marker in the tumor can predict who benefits most from the treatment.